ZIOPHARM (ZIOP) Appoints CMO Hagop Youssoufian to Oversee Clinical Ops
Tweet Send to a FriendGet Alerts ZIOP Hot Sheet
Down)
Trade ZIOP Now!
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced a new executive leadership team reporting to Jonathan Lewis, M.D., Ph.D., Chief Executive Officer. Under this new structure, Hagop Youssoufian, M.Sc., M.D., President of Research and Development and Chief Medical Officer, will, in addition to his current responsibilities, assume oversight of all regulatory affairs and clinical operations, and Caesar J. Belbel, Executive Vice President, Chief Legal Officer and Secretary, will add responsibility for corporate and business development. Jason A. Amello, Executive Vice President and Chief Financial Officer, will continue to be responsible for finance and information technology, and Lynn M. Ferrucci, Senior Vice President, Human Resources, will continue to oversee human resources.
In conjunction with the introduction of the new reporting structure, Richard E. Bagley, President, Chief Operating Officer and Director, is leaving the Company and stepping down from the Company's Board of Directors. Additionally, Mark Thornton, M.D., Ph.D., Executive Vice President, Government Affairs, Health Policy and Advocacy and Chief Quality Compliance Officer, is leaving the Company to pursue other opportunities. Both Mr. Bagley and Dr. Thornton are expected to remain available to ZIOPHARM on an advisory basis. With Dr. Thornton's departure, ZIOPHARM will no longer maintain an office in Germantown, MD.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
In conjunction with the introduction of the new reporting structure, Richard E. Bagley, President, Chief Operating Officer and Director, is leaving the Company and stepping down from the Company's Board of Directors. Additionally, Mark Thornton, M.D., Ph.D., Executive Vice President, Government Affairs, Health Policy and Advocacy and Chief Quality Compliance Officer, is leaving the Company to pursue other opportunities. Both Mr. Bagley and Dr. Thornton are expected to remain available to ZIOPHARM on an advisory basis. With Dr. Thornton's departure, ZIOPHARM will no longer maintain an office in Germantown, MD.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Stephen Hester to Step Down as CEO of RBS (RBS) Later in FY13
- Genetic Tech (GENE) Updates on Impact of SCOTUS Ruling on Gene Patenting
- Retail Properties of America (RPAI) Names Thomas Sargeant as Director
Create E-mail Alert Related Categories
Management Changes
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
